secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-269388
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q3 net loss widens to $34.9M; revenue ex-PAXLOVID falls 57% to $9.3M
----------------------------------------------------------------------------

- Net loss of $34.9M ($0.50/share) vs $10.0M loss ($0.15) in Q3 2022; adjusted loss $17.9M ($0.26) excludes restructuring/impairments.
- Total revenue $9.3M, down 73% YoY including PAXLOVID; ex-PAXLOVID revenue down 57% to $9.3M.
- Cash $74.6M; expects runway to positive cash flow around end of 2026.
- Reaffirms FY2023 guidance: product revenue $30-35M (ex-PAXLOVID), R&D revenue $21-24M, gross margin 55-65%.
- ECO Synthesis platform on track for gram-scale synthesis by year-end; dsRNA ligase wide availability in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000119312523269388/0001193125-23-269388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000119312523269388/d581655d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-269388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer